58.9 F
Laguna Hills
Friday, Feb 14, 2025
-Advertisement-

Edwards Stock Falls After Lowering Outlook

CEO cites ‘slower-than-expected growth'

Edwards Lifesciences Corp. (NYSE: EW) stock took a hit today after the company lowered its sales outlook for its transcatheter aortic heart-valve replacement unit.

Shares plummeted 17% to $72 in after-hours trading following the announcement.

The company now expects TAVR sales to grow by 5% to 7%, down from its prior outlook of 8% to 10% growth, based on current trends, according to the release.

Edwards reported “slower-than-expected growth in TAVR” for the second quarter, said Chief Executive Bernard Zovighian.

The company also announced it has entered into an agreement to acquire JenaValve Technology and Endotronix in a deal totaling in a combined $1.2 billion. Both acquisitions are expected to close in 2025.

“These acquisitions expand our opportunities to address the unmet needs of aortic regurgitation and heart failure patients around the world,” Zovighian said in a statement.

Want more from the best local business newspaper in the country?

Sign-up for our FREE Daily eNews update to get the latest Orange County news delivered right to your inbox!

Yuika Yoshida
Yuika Yoshida
Yuika Yoshida has been a reporter covering healthcare, innovation and education at the Orange County Business Journal since 2023. Previous bylines include JapanUp! Magazine and Stu News Laguna. She received her bachelor's degree in literary journalism from the University of California, Irvine. During her time at UC Irvine, she was the campus news editor for the official school paper and student writer for the Samueli School of Engineering. Outside of writing, she enjoys musical theater and finding new food spots within Orange County.
-Advertisement-

Featured Articles

-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-

Related Articles

-Advertisement-
-Advertisement-